Buy Farxiga

Farxiga

Farxiga: Dapagliflozin Overview

Farxiga (dapagliflozin) is a prescription medication used to improve blood-sugar control in adults with type 2 diabetes. It belongs to the class of sodium-glucose co-transport-2 (SGLT2) inhibitors and is available as a 5 mg and 10 mg oral pill. In Hong Kong, Farxiga is regulated by the Department of Health and requires a physician’s prescription.

How Farxiga Works in the Body

• Targeted Mechanism - Dapagliflozin blocks the SGLT2 proteins in the kidney’s proximal tubules. This reduces the reabsorption of filtered glucose, allowing excess glucose to be excreted in the urine.
• Resulting Effects - By promoting urinary glucose loss, Farxiga lowers circulating blood-glucose levels independent of insulin.
• Onset and Duration - Blood-glucose reduction typically begins within a few days of the first dose, with the full effect seen after about one week of steady dosing.
• Pharmacokinetics - Oral absorption is rapid; peak plasma concentrations occur 1-2 hours after ingestion. The drug is minimally metabolized and is excreted largely unchanged via the kidneys.

Conditions Treated with Farxiga

• Type 2 Diabetes Mellitus - Approved in Hong Kong for adults with type 2 diabetes to improve glycemic control, often in combination with diet, exercise, and other antihyperglycemic agents.
• Heart Failure (Reduced Ejection Fraction) - While not a primary diabetes indication, Farxiga carries an additional regulatory approval in many regions for reducing the risk of cardiovascular death and hospitalization for heart failure. This article focuses on the diabetes indication.

Off-Label and Investigational Uses

• Chronic Kidney Disease (CKD) - Clinical studies have explored dapagliflozin’s renal protective effects, but its use for CKD without diabetes remains off-label.
• Type 1 Diabetes - Some experimental protocols have evaluated SGLT2 inhibition in type 1 diabetes, yet regulatory agencies have not approved Farxiga for this population due to an elevated risk of ketoacidosis.

Off-label use requires close medical supervision and a personalized risk assessment.

Who Should Use Farxiga? Contraindications

Absolute Contraindications

• Known hypersensitivity to dapagliflozin or any tablet excipients.
• End-stage renal disease (eGFR < 15 mL/min/1.73 m²) or patients on chronic dialysis.
• Pregnancy - safety has not been established; Farxiga is not recommended.

Relative Contraindications

• Moderate renal impairment (eGFR 15-45 mL/min/1.73 m²); dose may need adjustment, and benefits should be weighed against risks.
• History of diabetic ketoacidosis (DKA).
• Concomitant use of strong diuretics leading to volume depletion.

Special Populations

• Lactation - Dapagliflozin appears in breast milk; breastfeeding mothers should discuss alternatives with their healthcare provider.
• Elderly - Age-related renal decline may necessitate closer monitoring of kidney function.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Increased urinary frequency or urgency (often mild).
• Genital mycotic infections (e.g., yeast infections) - more common in women.
• Mild dehydration due to osmotic diuresis.

Serious Adverse Events

• Ketoacidosis - Rare but potentially life-threatening; symptoms include nausea, vomiting, abdominal pain, rapid breathing, and mental status changes.
• Severe Hypotension - Particularly when combined with other diuretics or in patients with low blood pressure.
• Acute Kidney Injury - May occur in volume-depleted states; monitor renal function.

Drug Interactions

• Insulin and Sulfonylureas - Additive glucose-lowering effect can increase hypoglycemia risk; dose adjustments may be needed.
• Loop or Thiazide Diuretics - Combined use can exacerbate dehydration and hypotension.
• Rifampin and Other Strong CYP3A4 Inducers - May reduce dapagliflozin plasma concentrations, potentially diminishing efficacy.

Patients should inform their prescriber of all medications, supplements, and herbal products before starting Farxiga.

Food and Lifestyle Interactions

• Farxiga can be taken with or without food; no specific dietary restrictions are required.
• Excessive alcohol intake can increase the risk of hypoglycemia when combined with other glucose-lowering drugs.
• Alcohol also predisposes to ketoacidosis; caution is advised.
• No known effect on the ability to drive or operate machinery, but symptomatic low blood pressure or dehydration may impair performance.

How to Take Farxiga

• Standard Dosing - The usual starting dose is 5 mg taken once daily. After at least 30 days, the dose may be increased to 10 mg once daily if additional glycemic control is needed and renal function is adequate.
• Administration - Swallow the tablet whole with a glass of water. The pill may be taken at any time of day, with or without meals.
• Missed Dose - If a dose is missed, take it as soon as remembered on the same day. Do not double the dose the next day.
• Overdose - Symptoms may include excessive urination, dehydration, and low blood pressure. Seek emergency medical care; supportive care is the primary treatment.
• Discontinuation - No tapering is required for dapagliflozin. However, abrupt cessation may cause a rise in blood glucose; a healthcare provider should guide any medication changes.

Monitoring and Follow-Up

• Renal Function - Check serum creatinine and eGFR before initiating therapy and periodically thereafter (e.g., every 6-12 months).
• Blood Glucose - Regular self-monitoring of glucose is essential, especially during dose adjustments.
• Electrolytes - Monitor sodium and potassium if the patient is also on diuretics.
• Signs of Ketoacidosis - Educate patients to recognize early symptoms and seek prompt evaluation.

Storage and Handling

• Store Farxiga tablets at room temperature (20-25 °C/68-77 °F), away from excess moisture and heat.
• Keep the bottle tightly closed and out of reach of children.
• Do not use tablets after the expiration date printed on the packaging.
• Unused medication should be disposed of according to local pharmacy or waste-collection guidelines.

Medication-Specific Glossary

SGLT2 Inhibitor

A drug class that blocks sodium-glucose co-transport-2 proteins in the kidney, promoting urinary glucose excretion.

eGFR (Estimated Glomerular Filtration Rate)

A calculation that estimates kidney filtration capacity; used to assess renal eligibility for dapagliflozin.

Ketoacidosis

A metabolic emergency characterized by high blood ketone levels, acidosis, and often elevated blood glucose, requiring urgent treatment.

Glucosuria

The presence of glucose in the urine, which occurs when dapagliflozin reduces renal glucose reabsorption.

Medical Disclaimer

This article provides educational information about Farxiga and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.